共 47 条
[1]
Patouillard E(2017)Global investment targets for malaria control and elimination between 2016 and 2030 BMJ Glob Health 2 e000176-702
[2]
Griffin J(2013)Trends in chloroquine resistance marker , Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania Malar J 12 1-13
[3]
Bhatt S(2018)Therapeutic efficacy of Sulfadoxine-Pyrimethamine and prevalence of resistance markers in Tanzania Prior to revision of malaria treatment policy: Plasmodium falciparum Dihydrofolate Reductase and Dihydropteroate synthase mutations in monitoring in vivo re Am J Trop Med Hyg 71 696-405
[4]
Ghani A(2005)Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug Malar J 4 1-13949
[5]
Cibulskis R(1994)Sequence variation of the Hydroxymethyldihydropterin Pyrophosphokinase: Dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to Sulfadoxine Eur J Biochem 224 397-9
[6]
Mohammed A(1997)Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum Proc Natl Acad Sci U S A 94 13944-702
[7]
NDEJEMBI M(2015)High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania Malar J 14 1-8
[8]
Mubyazi GM(2004)Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo re Am J Trop Med Hyg 71 696-22
[9]
Gonzalez-Block MA(2016)Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine-pyrimethamine in Tanzania Malar J 15 1-12
[10]
Brooks DR(2007)Malaria in pregnancy: linking immunity and pathogenesis to prevention Am J Trop Med Hyg 77 14-7